Lenvatinib-d<sub>4</sub>

Lenvatinib-d4

CAT N°: 28615
Price:

396.00 336.60

Lenvatinib-d4 is intended for use as an internal standard for the quantification of lenvatinib (Item No. 19375) by GC- or LC-MS. Lenvatinib is an inhibitor of the receptor tyrosine kinases VEGF receptor 2 (VEGFR2) and VEGFR3 (IC50s = 4.0 and 5.2 nM, respectively).{32663,32664} It is slightly less potent against the related kinases VEGFR1, FGFR1, PDGFR?, PDGFR?, and Kit (IC50s = 22, 46, 51, 39, and 100 nM, respectively).{32663} Lenvatinib (30 mg/kg, twice per day) reduces tumor growth in an H146 small cell lung cancer mouse xenograft model and induces tumor regression when administered at a dose of 100 mg/kg twice per day. Formulations containing lenvatinib have been used in the treatment of differentiated thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma.

We also advise you